

# Mario Tiribelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2131005/publications.pdf>

Version: 2024-02-01

256  
papers

4,829  
citations

117571

34  
h-index

128225

60  
g-index

260  
all docs

260  
docs citations

260  
times ranked

5227  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
2	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
3	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	1.3	10
4	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454.	2.0	7
5	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. <i>Current Oncology</i> , 2022, 29, 4970-4980.	0.9	2
6	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
7	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
8	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIKIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	1.3	9
9	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	0.8	9
10	Haploidentical transplant after failure of a first allogeneic transplant: A long and winding road. <i>European Journal of Haematology</i> , 2021, 106, 871-872.	1.1	0
11	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
12	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816.	3.3	3
13	Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center. <i>Turkish Journal of Haematology</i> , 2021, 38, 119-125.	0.2	2
14	The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population. <i>Cancer Medicine</i> , 2021, 10, 6310-6316.	1.3	13
15	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	1.3	6
16	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
17	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	0.8	14
18	Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. <i>Targeted Oncology</i> , 2021, 16, 823-838.	1.7	5

#	ARTICLE	IF	CITATIONS
19	BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies. <i>Journal of Clinical Medicine</i> , 2021, 10, 5096.	1.0	3
20	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487.	0.6	0
21	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 3617-3617.	0.6	1
22	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581.	0.6	1
23	Asciminib as a new option in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2021, 17, 5003-5005.	1.1	6
24	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. <i>Bone Marrow Transplantation</i> , 2020, 55, 708-716.	1.3	23
25	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	3.3	35
26	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
27	CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S236-S237.	0.2	0
28	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	0.8	9
29	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	2.8	6
30	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57
31	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. <i>Annals of Hematology</i> , 2020, 99, 65-72.	0.8	13
32	Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 588-595.	0.2	11
33	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
34	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020, 136, 35-36.	0.6	1
35	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44.	0.6	2
36	BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC". <i>Blood</i> , 2020, 136, 9-10.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
38	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
39	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	1
40	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
41	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	0.6	0
42	Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study). <i>Blood</i> , 2020, 136, 42-42.	0.6	1
43	First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
44	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	0.8	17
45	Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. <i>Oncology and Therapy</i> , 2019, 7, 95-100.	1.0	8
46	Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. <i>Annals of Hematology</i> , 2019, 98, 2609-2611.	0.8	13
47	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	0.8	5
48	Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key?. <i>European Journal of Haematology</i> , 2019, 103, 272-273.	1.1	24
49	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
50	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
51	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
52	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	6.9	45
53	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
54	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019, 134, 4145-4145.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Blood</i> , 2019, 134, 661-661.	0.6	5
56	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
57	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
58	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4188-4188.	0.6	0
59	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	0.6	1
60	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174.	0.6	2
61	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. <i>Blood</i> , 2019, 134, 4142-4142.	0.6	0
62	Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study. <i>Blood</i> , 2019, 134, 5909-5909.	0.6	0
63	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicineâ€”Results from the Italian â€”Back to Lifeâ€” project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	1.5	9
64	Healthâ€”related quality of life in patients with chronic myeloid leukemia receiving firstâ€”line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	2.0	22
65	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
66	Efficacy and safety of ruxolitinib in intermediateâ€”IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
67	The significance of early warning in chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 265-266.	1.0	1
68	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
69	Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. <i>Leukemia Research</i> , 2018, 74, 75-79.	0.4	14
70	Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?. <i>Leukemia Research</i> , 2018, 74, 55-56.	0.4	2
71	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
72	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 623-628.	1.0	10

#	ARTICLE	IF	CITATIONS
73	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	1.3	84
74	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7
75	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
76	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	0.6	1
77	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018, 132, 45-45.	0.6	4
78	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732.	0.6	1
79	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	0.6	8
80	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	0.6	10
81	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	0.6	3
82	Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. <i>Oncotarget</i> , 2018, 9, 14219-14227.	0.8	13
83	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	0.6	0
84	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. <i>Blood</i> , 2018, 132, 1726-1726.	0.6	0
85	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	0.6	0
86	Efficacy and Safety of Bosutinib in Chronic Phase CML Patients Developing Pleural Effusion Under Dasatinib Therapy. <i>Blood</i> , 2018, 132, 5439-5439.	0.6	0
87	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. <i>Blood</i> , 2018, 132, 4251-4251.	0.6	0
88	Impact of fludarabine-based induction therapy on outcome of FLT3~NPM1+ cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, E45-E47.	2.0	1
89	High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FIT3-ITD-/NPM1+ patients. <i>Leukemia Research</i> , 2017, 58, 31-38.	0.4	19
90	The BCR~ABL1 transcript type influences response and outcome in P+ Philadelphia chromosome~positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	2.0	71

#	ARTICLE	IF	CITATIONS
91	ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML. <i>European Journal of Haematology</i> , 2017, 99, 269-274.	1.1	8
92	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
93	Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S313-S314.	0.2	1
94	ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4934-4935.	2.0	0
95	How could patient reported outcomes improve patient management in chronic myeloid leukemia?. <i>Expert Review of Hematology</i> , 2017, 10, 9-14.	1.0	14
96	CD200 in hematological malignancies: just a diagnostic tool or more?. <i>Journal of Laboratory and Precision Medicine</i> , 2017, 2, 77-77.	1.1	0
97	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017, 8, 29906-29913.	0.8	22
98	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
99	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	2.0	10
100	ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1621-1626.	2.0	4
101	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	2.3	24
102	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	1.7	22
103	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219.	0.8	18
104	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128.	0.6	4
105	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. <i>Blood</i> , 2016, 128, 3068-3068.	0.6	1
106	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070.	0.6	10
107	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251.	0.6	2
108	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016, 128, 942-942.	0.6	2



#	ARTICLE	IF	CITATIONS
109	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
110	Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study. <i>Blood</i> , 2016, 128, 5434-5434.	0.6	0
111	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016, 128, 5464-5464.	0.6	0
112	Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). <i>Blood</i> , 2016, 128, 3096-3096.	0.6	0
113	Imatinib-treated Chronic Myeloid Leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. <i>Haematologica</i> , 2015, 100, e299-301.	1.7	9
114	<scp>ABCG</scp>2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. <i>American Journal of Hematology</i> , 2015, 90, 784-789.	2.0	16
115	Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. <i>Oncotarget</i> , 2015, 6, 30212-30221.	0.8	37
116	Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement. <i>Annals of Hematology</i> , 2015, 94, 1423-1424.	0.8	3
117	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
118	Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. <i>Internal and Emergency Medicine</i> , 2015, 10, 451-460.	1.0	7
119	Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy. <i>American Journal of Hematology</i> , 2015, 90, E135-E137.	2.0	1
120	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	1.7	39
121	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015, 5, e347-e347.	2.8	29
122	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.4	57
123	Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. <i>Annals of Hematology</i> , 2015, 94, 873-874.	0.8	9
124	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015, 126, 2792-2792.	0.6	2
125	Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC. <i>Blood</i> , 2015, 126, 597-597.	0.6	17
126	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. <i>Blood</i> , 2015, 126, 4046-4046.	0.6	0
128	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598.	0.6	0
129	Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/Åµl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kinase Inhibitors (TKIs). <i>Blood</i> , 2015, 126, 4028-4028.	0.6	0
130	Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. <i>American Journal of Hematology</i> , 2014, 89, 933-934.	2.0	3
131	Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology. <i>Oncogene</i> , 2014, 33, 2876-2887.	2.6	52
132	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	2.0	14
133	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.4	30
134	EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. <i>Annals of Hematology</i> , 2014, 93, 163-164.	0.8	8
135	Overcoming therapy failure in elderly patients with chronic myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 353-365.	0.7	0
136	Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> . 2013;121(26):5138-5144.. <i>Blood</i> , 2014, 123, 2902-2902.	0.6	0
137	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. <i>Blood</i> , 2014, 124, 4532-4532.	0.6	0
138	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. <i>Blood</i> , 2014, 124, 1794-1794.	0.6	1
139	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109.	0.8	59
140	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	1.3	36
141	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 179-183.	0.8	12
142	EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. <i>Leukemia Research</i> , 2013, 37, 1457-1460.	0.4	11
143	BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. <i>American Journal of Hematology</i> , 2013, 88, 848-852.	2.0	26
144	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	0.6	49

#	ARTICLE	IF	CITATIONS
145	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403.	1.7	42
146	Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. <i>Haematologica</i> , 2013, 98, e28-e29.	1.7	21
147	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013, 122, 258-258.	0.6	2
148	Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2013, 122, 4082-4082.	0.6	1
149	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013, 122, 4000-4000.	0.6	0
150	EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The "Gruppo Triveneto LMC". <i>Blood</i> , 2013, 122, 4024-4024.	0.6	0
151	Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The "Gruppo Triveneto LMC". <i>Blood</i> , 2013, 122, 2732-2732.	0.6	3
152	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. <i>Haematologica</i> , 2012, 97, 1722-1730.	1.7	44
153	Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. <i>British Journal of Cancer</i> , 2012, 107, 904-909.	2.9	100
154	Histone post-translational modifications associated to BAALC expression in leukemic cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 721-725.	1.0	8
155	Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia. <i>Annals of Hematology</i> , 2012, 91, 1937-1943.	0.8	9
156	Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 93-100.	2.0	29
157	Evaluation of residual CD34 <sup>+</sup> Ph <sup>+</sup> progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012, 118, 5265-5269.	2.0	13
158	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. <i>Blood</i> , 2012, 120, 3784-3784.	0.6	5
159	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. <i>Blood</i> , 2012, 120, 692-692.	0.6	2
160	BCR-ABL kinase domain mutations and resistance in Ph <sup>+</sup> acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6531-6531.	0.8	0
161	Blood Cells Dynamic and Thrombo-Haemorrhagic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.. <i>Blood</i> , 2012, 120, 2839-2839.	0.6	0
162	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. <i>Blood</i> , 2012, 120, 2797-2797.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599.	0.6	97
164	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.4	28
165	Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. <i>Cancer</i> , 2011, 117, 2156-2162.	2.0	21
166	Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5649-5655.	3.2	17
167	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , 2011, 118, 2756-2756.	0.6	7
168	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. <i>Blood</i> , 2011, 118, 2770-2770.	0.6	1
169	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. <i>Blood</i> , 2011, 118, 453-453.	0.6	1
170	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. <i>Blood</i> , 2011, 118, 1682-1682.	0.6	0
171	Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement. <i>Blood</i> , 2011, 118, 575-575.	0.6	0
172	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011, 118, 786-786.	0.6	5
173	Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. <i>Blood</i> , 2011, 118, 1026-1026.	0.6	0
174	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. <i>Blood</i> , 2011, 118, 4445-4445.	0.6	0
175	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. <i>Blood</i> , 2011, 118, 1686-1686.	0.6	0
176	Two novel NPM1 mutations in a therapy-responder AML patient. <i>Hematological Oncology</i> , 2010, 28, 151-155.	0.8	7
177	Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. <i>Leukemia Research</i> , 2010, 34, 942-945.	0.4	36
178	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 480-483.	3.3	7
179	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2010, 16, 1824-1833.	3.2	23
180	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. <i>Blood</i> , 2010, 116, 2293-2293.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413.	0.6	2
182	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359.	0.6	14
183	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, "Deep" and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2720-2720.	0.6	0
184	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. Blood, 2010, 116, 2279-2279.	0.6	0
185	Q141K Polymorphism of ABCG2 Protein Is Associated with Poor Prognosis In Adult Acute Myeloid Leukemia Treated with a Idarubicin-Based Chemotherapy Protocol. Blood, 2010, 116, 4941-4941.	0.6	0
186	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	0.6	0
187	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients " EudraCT Number 2007"005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	0.6	0
188	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. Blood, 2010, 116, 2273-2273.	0.6	0
189	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. Blood, 2010, 116, 1229-1229.	0.6	0
190	Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. Blood, 2010, 116, 2294-2294.	0.6	1
191	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. Clinical Cancer Research, 2009, 15, 1059-1063.	3.2	28
192	Quantitative assessment of <i>WT1</i> gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. European Journal of Haematology, 2009, 82, 61-68.	1.1	78
193	FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience. American Journal of Hematology, 2009, 84, 690-692.	2.0	2
194	Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. British Journal of Haematology, 2009, 145, 424-426.	1.2	2
195	Unexpected phenotype of a typical <i>NPM1</i> mutant. British Journal of Haematology, 2009, 147, 760-763.	1.2	4
196	Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia Research, 2009, 33, 174-177.	0.4	34
197	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood, 2009, 113, 4300-4308.	0.6	83
198	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood, 2009, 114, 4933-4938.	0.6	203

#	ARTICLE	IF	CITATIONS
199	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. Blood, 2009, 114, 2205-2205.	0.6	8
200	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow up of 30 to 92 Months.. Blood, 2009, 114, 3894-3894.	0.6	1
201	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	0.6	3
202	Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY.. Blood, 2009, 114, 1118-1118.	0.6	1
203	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. Blood, 2009, 114, 2211-2211.	0.6	0
204	Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy. American Journal of Hematology, 2008, 83, 517-518.	2.0	17
205	Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leukemia Research, 2008, 32, 1800-1808.	0.4	36
206	What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?. Bone Marrow Transplantation, 2008, 42, 207-208.	1.3	8
207	Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases. European Journal of Haematology, 2008, 81, 354-363.	1.1	29
208	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. Journal of Leukocyte Biology, 2008, 83, 434-437.	1.5	14
209	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- $\alpha$ : 5-year outcome. Haematologica, 2008, 93, 770-774.	1.7	53
210	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2008, 112, 181-181.	0.6	19
211	Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial. Blood, 2008, 112, 3998-3998.	0.6	0
212	Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study. Blood, 2008, 112, 5223-5223.	0.6	0
213	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. Current Drug Metabolism, 2007, 8, 395-403.	0.7	69
214	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR $\alpha$ -positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007, 92, 1173-1179.	1.7	198
215	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. Neoplasia, 2007, 9, 853-861.	2.3	41
216	The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematological Oncology, 2007, 25, 38-43.	0.8	37



#	ARTICLE	IF	CITATIONS
217	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. <i>Journal of Cellular Physiology</i> , 2007, 213, 229-236.	2.0	11
218	Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. <i>Bone Marrow Transplantation</i> , 2007, 39, 189-191.	1.3	14
219	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. <i>Leukemia</i> , 2007, 21, 1442-1450.	3.3	22
220	Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2007, 136, 87-95.	1.2	20
221	Brain Natriuretic Peptide (BNP) Level as Marker of Cardiac Function in Imatinib - Treated Chronic Myeloid Leukemia Patients: No Evidence of Cardiotoxicity of Imatinib Therapy.. <i>Blood</i> , 2007, 110, 2948-2948.	0.6	9
222	Systematic Evaluation of Hypereosinophilic Syndrome-Related Organ Damage According to FIP1L1-PDGFR $\alpha$ Status and Response to the Therapy: Analysis from Prospective Clinical Trial with Imatinib Mesylate.. <i>Blood</i> , 2007, 110, 3557-3557.	0.6	21
223	Fungal and Bacterial Infections in Acute Myeloid Leukemia Patients Treated with Induction Regimens Including Fludarabine: A Retrospective Analysis of 224 Cases.. <i>Blood</i> , 2007, 110, 4351-4351.	0.6	5
224	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006, 107, 4122-4129.	0.6	156
225	Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 517-524.	1.1	2
226	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 158-164.	2.0	33
227	Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. <i>American Journal of Hematology</i> , 2006, 81, 355-357.	2.0	23
228	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 7374-7379.	3.2	475
229	A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants.. <i>Blood</i> , 2006, 108, 4849-4849.	0.6	0
230	FIP1L1-PDGFR $\alpha$ Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.. <i>Blood</i> , 2006, 108, 2700-2700.	0.6	3
231	The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. <i>Haematologica</i> , 2006, 91, 825-8.	1.7	92
232	Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. <i>European Journal of Haematology</i> , 2005, 75, 227-233.	1.1	64
233	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2005, 205, 246-252.	2.0	26
234	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. <i>American Journal of Pathology</i> , 2005, 167, 1599-1607.	1.9	43



#	ARTICLE	IF	CITATIONS
235	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML. <i>Blood</i> , 2005, 106, 435-435.	0.6	4
236	The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia. <i>Blood</i> , 2005, 106, 3251-3251.	0.6	1
237	Aberrant Expression of Trail in B Chronic Lymphocytic Leukemia (B-CLL) Cells. <i>Blood</i> , 2005, 106, 4976-4976.	0.6	0
238	Biological and clinical features of T-biphenotypic acute leukaemia: report from a single centre. <i>British Journal of Haematology</i> , 2004, 125, 814-815.	1.2	12
239	Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogeneic hematopoietic stem cell transplantation in Philadelphia-positive leukemias. <i>Bone Marrow Transplantation</i> , 2004, 34, 827-828.	1.3	5
240	Abdominal abscess and <i>Hafnia alvei</i> septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. <i>Journal of Infection and Chemotherapy</i> , 2004, 10, 303-306.	0.8	7
241	Plasma Cell Leukemia Occurring in a Patient with Thrombocytopenia Treated with Hydroxyurea and Busulphan. <i>Leukemia and Lymphoma</i> , 2004, 45, 821-824.	0.6	13
242	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFR $\alpha$ Rearrangement Can Be Effectively Treated with Imatinib. <i>Blood</i> , 2004, 104, 1504-1504.	0.6	5
243	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis. <i>Blood</i> , 2004, 104, 4655-4655.	0.6	0
244	A phase II study of $\alpha$ -interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. <i>Leukemia</i> , 2003, 17, 554-559.	3.3	11
245	Anti-CD20 Therapy for Chronic Lymphocytic Leukemia-associated Autoimmune Diseases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1951-1955.	0.6	83
246	Nocardiosis with Favourable Clinical Outcome in Progressive B-chronic Lymphocytic Leukaemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 1893-1894.	0.6	0
247	Endogenous endophthalmitis following disseminated fungemia due to <i>Fusarium solani</i> in a patient with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2002, 68, 314-317.	1.1	29
248	Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. <i>Annals of Hematology</i> , 2002, 81, 462-466.	0.8	28
249	Reply to Pfirmann and Hasford. <i>British Journal of Haematology</i> , 2001, 114, 241-242.	1.2	2
250	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. <i>British Journal of Haematology</i> , 2000, 111, 644-646.	1.2	0
251	Screening of Bcr-Abl Transcripts in Philadelphia Negative Essential Thrombocytopenia. <i>Leukemia and Lymphoma</i> , 2000, 39, 339-341.	0.6	0
252	Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation. <i>British Journal of Haematology</i> , 2000, 111, 662-667.	1.2	6

#	ARTICLE	IF	CITATIONS
253	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. British Journal of Haematology, 2000, 111, 587-595.	1.2	31
254	Single nucleotide polymorphisms of the factor IX gene for linkage analysis in the southern Chinese population. British Journal of Haematology, 2000, 111, 540-543.	1.2	2
255	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 644-646.	1.2	16
256	Molecular landscape in adult acute myeloid leukemia: where we are where we going?. Journal of Laboratory and Precision Medicine, 0, 4, 17-17.	1.1	2